190 related articles for article (PubMed ID: 14502103)
1. Antiatherogenic properties of metformin: the experimental evidence.
Mamputu JC; Wiernsperger NF; Renier G
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S71-6. PubMed ID: 14502103
[TBL] [Abstract][Full Text] [Related]
2. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
3. Is metformin more than an oral hypoglycaemic agent?
Vague P
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S5-7. PubMed ID: 14502095
[No Abstract] [Full Text] [Related]
4. [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Tamura H; Mokuno H; Daita H
Nihon Rinsho; 2006 Nov; 64(11):2119-25. PubMed ID: 17087306
[TBL] [Abstract][Full Text] [Related]
5. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
6. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Després JP
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
[TBL] [Abstract][Full Text] [Related]
7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of metformin on haemostasis and vascular function in man.
Grant PJ
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
[TBL] [Abstract][Full Text] [Related]
9. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
Palumbo PJ
J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
11. [New clinical data with metformin therapy in patients with diabetes mellitus].
Jermendy G
Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
[TBL] [Abstract][Full Text] [Related]
12. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Bailey CJ
Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
[TBL] [Abstract][Full Text] [Related]
14. Insulin in the early management of diabetic complications.
Miles JM
J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
[TBL] [Abstract][Full Text] [Related]
15. [Current role of metformin in treatment of diabetes mellitus type 2].
Janssen JA
Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1900-2. PubMed ID: 11045135
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
17. Metformin use among individuals at risk for type 2 diabetes.
Kuller LH
Curr Diab Rep; 2012 Jun; 12(3):265-73. PubMed ID: 22399368
[TBL] [Abstract][Full Text] [Related]
18. [Metformin in the treatment of type 2 diabetes in overweighted or obese patients].
Martín Muñoz MC; Díaz JM; Muros Bayo JM; González Alvaro A; Costa Zamora P
An Med Interna; 2005 Dec; 22(12):579-85. PubMed ID: 16454597
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitisation in the treatment of Type 2 diabetes.
Tadayyon M; Smith SA
Expert Opin Investig Drugs; 2003 Mar; 12(3):307-24. PubMed ID: 12605557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
